ArticleImmunity & ageing : I & A2020

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.

Danay Saavedra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.